Oerlemans, Anoek M.
Rommelse, Nanda N. J.
Buitelaar, Jan K.
Hartman, Catharina A.
Funding for this research was provided by:
Center for Integration of Medicine and Innovative Technology (115300 (EU-AIMS))
Seventh Framework Programme
European Community's Horizon 2020 Program (642996 (BRAINVIEW))
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (024.001.003, GB-MW 940-38-011, Social Sciences Council grants GB-MaGW 480-01-006, GB-MaGW 480-07-001, GB-MaGW 452-04-314, GB-MaGW 452-06-004, Large-sized investment grant 175.010.2003.005, Longitudinal Survey, Panel Funding 481-08-013, 481-11-001)
ZonMw (Brainpower grant 100-001-004, Risk Behaviour, Dependence grants 60-60600-97-118, Culture, Health grant 261-98-710)
Dutch Ministry of Justice
European Science Foundation (EuroSTRESS FP-006)
Biobanking and Biomolecural Resources Research Infrastructure (BBMRI-NL (CP32))
Article History
Received: 17 September 2017
Accepted: 15 January 2018
First Online: 30 January 2018
Compliance with ethical standards
:
: The Dutch Central Committee on Research Involving Human Subjects approved all the TRAILS study protocols.
: All children and their parents provided written informed consent to participate.
: J.K. Buitelaar has been a consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Organon/Shering Plough, UCB, Shire, Medice, Roche and Servier. All the other authors have no conflict of interest to disclose.